The Therapeutic Goods Administration (TGA) conducted a public consultation seeking comments from interested parties on changes to current requirements for advisory statements for labels of non-prescription medicines containing more than 1.5 per cent lidocaine (lignocaine) for topical oral use, as included in the Required Advisory Statements for Medicine Labels (RASML) document.
For more information and to participate in the consultation, please visit consultation hub.
The consultation opened on Tuesday 6 April 2021. Interested parties responded by close of business, Tuesday 18 May 2021.
Information on submissions received and the outcomes of the consultation are available from the consultation hub.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.